News Briefing channel feed

Sesen Bio tri­al marred by mis­con­duct — re­port; Bris­tol My­ers picks up de­vel­op­ment of AI out­fit's im­munol­o­gy drug

4 years ago

Au­rinia gets two new as­sets in ac­qui­si­tion, li­cens­ing deal; Shorla preps T-cell leukemia drug for com­mer­cial­iza­tion

4 years ago

Can­cer spe­cial­ist Hi­ber­Cell snaps up an­a­lyt­ics, com­pu­ta­tion­al tools in all-stock buy­out; Prax­is re­veals new per­i­menopausal de­pres­sion da­ta

4 years ago

Mus­tang inks a deal for in vi­vo CAR-T tech from the Mayo Clin­ic; How a spilled cup of tea land­ed one biotech $11.7 mil­lion

4 years ago

Pe­ter Thiel-backed ATAI launch­es new Salvia-fo­cused biotech; Pur­due bank­rupt­cy tri­al ex­pect­ed to be­gin to­day — re­port

4 years ago

Pur­due sub­sidiary nabs non-opi­oid drug for pain; Or­biMed backs small biotech's 'su­pe­ri­or' drug

4 years ago

Keytru­da keeps ex­pand­ing with an­oth­er pri­or­i­ty re­view; Medicxi-backed eye drop mak­er wins new fund­ing, re­gion­al deal

4 years ago

Ab­b­Vie hands over $20M for Alzheimer's, Parkin­son's drugs; Au­to­lus boost­ed by a PIM

4 years ago

Sen­ate Dems call to add Medicare drug price ne­go­ti­a­tions to rec­on­cil­i­a­tion bill; Cer­tara signs $310M buy­out of soft­ware com­pa­ny

4 years ago

Celu­lar­i­ty teams up with Aus­tralian biotech to de­vel­op CAR T-cell ther­a­py; For­mer Kin­nate CEO Stephen Kaldor reels in $50M for new biotech

4 years ago

Am­gen may see $3B+ in ad­di­tion­al tax­es; EQRx, Ab­Cellera ink an­ti­body de­vel­op­ment deal

4 years ago

Roche's PD-L1 fran­chise play­er nabs pri­or­i­ty re­view; One of world's first psy­che­delics re­search in­sti­tutes opens in Aus­tralia

4 years ago

FTC pulls re­main­ing case against Ab­b­Vie; New EU clin­i­cal tri­als sys­tem com­ing in 2022; Abing­worth bets big on CymaBay

4 years ago

Top Gilead can­cer re­searcher jumps to a start­up as Dan Chen ex­its; Arde­lyx gets that CRL we've been wait­ing for

4 years ago

Roche nabs pri­or­i­ty re­view for Eylea com­peti­tor; Italy's An­geli­ni eyes CNS, rare dis­ease star­tups with $35M Lu­mi­ra fund

4 years ago

US sells Wu-Tang Clan al­bum to cov­er Shkre­li debt; Or­biMed backs GSK vet­s' Chi­nese start­up

4 years ago

Mer­ck­'s wom­en's health spin­out snags mid-stage can­di­date for preterm birth; Keytru­da nails down TNBC ap­proval af­ter March CRL

4 years ago

Bay­er poach­es newest ear­ly R&D head from Roche; Glax­o­SmithK­line earns ex­pand­ed nod for Shin­grix

4 years ago

Mod­er­na es­tab­lish­es pub­lic health-fo­cused char­i­ty; FDA ap­proves As­traZeneca di­a­betes drug for pe­di­atric use

4 years ago

Al­bireo re­veals $385K price tag for new­ly ap­proved pru­ri­tis drug; Jen­nifer Doud­na's Cari­bou up­sizes IPO

4 years ago

As­traZeneca, Alex­ion close mas­sive $39B merg­er; blue­bird bio earns EU nod for Lenti-D as big split ap­proach­es

4 years ago

Rel­ma­da to ex­plore psy­che­del­ic av­enue in pur­suit of de­pres­sion treat­ment; Ital­ian man­u­fac­tur­er joins NYSE

4 years ago

Soros, Gates back medtech's move in­to a 'so­cial en­ter­prise'; Ag­ing an­ti-re­jec­tion drug earns fresh ap­proval

4 years ago

JAK in­hibitor PDU­FA dates ex­tend­ed again as safe­ty re­view con­tin­ues; Stem­son se­cures $15M to cure hair loss

4 years ago
First page Previous page 28293031323334 Next page Last page
A service from the Financial Times